Regulatory B Cells in Type 1 Diabetes

Boldison, Joanne; Rosa, Larissa Camargo da; Wong, F. Susan

doi:10.1007/978-1-0716-1237-8_22

Cited by 3 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role that cellular metabolism plays in altering immune cell function has become increasingly recognized, expanding the armamentarium of therapeutic targets for disease modulation. B cells have been shown to play critical roles in T1D development as antigen-presenting cells, antibody producing cells, and more recently, suppressive, regulatory B cells, highlighting multiple fates for B cells during development (36,(39)(40)(41)(42)(43)(44) and multiple opportunities to modulate immune responses. However, only B cell depletion has been tested in clinical trials to alter T1D disease course (45).…”

Section: Discussionmentioning

confidence: 99%

Altered B Cell Metabolic Pathways Characterize Type 1 Diabetes Progression

Conway,

Perez,

Swar-Eldahab

et al. 2024

Preprint

View full text Add to dashboard Cite

SUMMARYType 1 diabetes (T1D) results in immune-mediated destruction of insulin-producing beta cells I the pancreas. B cells have been identified as critical antigen presenting cells and their specificity drives disease progression. More recently, they have also been shown to have the capacity to develop into suppressive, regulatory B cells that ameliorate autoimmune disease in animal models of rheumatoid arthritis and multiple sclerosis. In these models, signaling through hypoxia-inducible factor 1α (HIF-1α) drives a glycolytic flux that facilitates expansion of regulatory B cells. Here we examine the relationship between B cell development, cellular metabolism, and HIF-1α to reveal that in a mouse model of autoimmune diabetes, B cells have distinct metabolic characteristics that change with disease progression. Further, response to hypoxia in autoimmune B cells is distinct from the response by non-autoimmune control B cells. Together, these data suggest that dysregulated HIF signaling may drive T1D progression and activation of HIF-1α to expand regulatory B cell populations may be a viable option for immune modulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Altered B Cell Metabolic Pathways Characterize Type 1 Diabetes Progression

Conway,

Perez,

Swar-Eldahab

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders

Brando,

Gatti

2024

Resistance to Anti-Cd20 Antibodies and Approaches for Their Reversal

View full text Add to dashboard Cite

Mechanisms underlying the development of type 1 diabetes in ART-treated people living with HIV: an enigmatic puzzle

Zaongo,

Zongo,

Chen

2024

Front. Immunol.

View full text Add to dashboard Cite

The immunopathogenesis of HIV infection remains poorly understood. Despite the widespread use of effective modern antiretroviral therapy (ART), people living with HIV (PLWH) are known to develop several comorbidities, including type 1 diabetes (T1DM). However, the etiology and critical mechanisms accounting for the onset of T1DM in the preceding context remain unknown. This article proposes to address this topic in order to provide further understanding and future research directions.

show abstract

Regulatory B Cells in Type 1 Diabetes

Cited by 3 publications

References 34 publications

Altered B Cell Metabolic Pathways Characterize Type 1 Diabetes Progression

Altered B Cell Metabolic Pathways Characterize Type 1 Diabetes Progression

Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders

Mechanisms underlying the development of type 1 diabetes in ART-treated people living with HIV: an enigmatic puzzle

Contact Info

Product

Resources

About